Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06432868 · ClinicalTrials.gov registry record · NA
Solarplast (R) Supplementation Effects Following High-intensity Resistance Exercise
A NA study of Muscle Damage, sponsored by Kent State University.
- Recruiting
- Registry status
- NA
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06432868: Recruiting NA study of Muscle Damage, sponsored by Kent State University.
NCT06432868 is a NA study of Muscle Damage that is actively recruiting participants, run by Kent State University. The registered enrollment target is 46 participants, above the 37-participant average among 6 other Muscle Damage trials with a reported enrollment target (24% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06432868, a NA study of Muscle Damage, is actively recruiting participants, sponsored by Kent State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of this investigation is to assess whether Solarplast (R) supplementation will improve recovery following heavy resistance exercise in active adults. The primary questions to be addressed are: Does Solarplast (R) decrease muscle damage and inflammation associated with heavy resistance exercise? Does Solarplast (R) reduce the decline in performance associate with heavy resistance exercise? Researchers will compare Solarplast (R) to a placebo (a look-alike substance that contains no active ingredients) to see if Solarplast (R) is effective at improving recovery. Participants will be asked to: Take Solarplast (R) or placebo daily for 4 weeks Visit the laboratory at least once per week to receive their supplement Report to the lab for 3 consecutive visits following supplementation to complete a heavy resistance training session and follow-up testing.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Solarplast (R)
Study Locations (1)
Ohio
- Kent State University - Exercise Science & Exercise Physiology - Kent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-04-17 |
| Est. Completion | 2025-03-31 |
| Phase | NA |
What NCT06432868 shows while recruiting
NCT06432868 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, above the 37-participant average among 6 other Muscle Damage trials with a reported enrollment target (24% higher).
The record links to 1 condition, with Muscle Damage appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06432868 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06432868 about?
NCT06432868 is a clinical study titled "Solarplast (R) Supplementation Effects Following High-intensity Resistance Exercise". The primary goal of this investigation is to assess whether Solarplast (R) supplementation will improve recovery following heavy resistance exercise in active adults. The primary questions to be addressed are: Does Solarplast (R) decrease muscle damage and inflammation associated with heavy resista...
What is the current status of trial NCT06432868?
This trial is currently recruiting. It is a NA study. The enrollment target is 46 participants. The study started on 2024-04-17. Estimated completion is 2025-03-31.
What conditions does trial NCT06432868 study?
This clinical trial studies the following conditions: Muscle Damage.
What interventions are being tested in trial NCT06432868?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Solarplast (R) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06432868?
This trial is sponsored by Kent State University, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06432868 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle Damage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effect of Vicia Faba Hydrolysate Supplementation on Muscle Strength Recovery
RECRUITING · NA
-
Comparing Two Eccentric Protocols on Muscle Damage
RECRUITING · NA
-
HIFEM and Radiofrequency for Muscular System Function Improvement
ACTIVE NOT RECRUITING · NA
-
Protein and Recovery From Exercise-induced Muscle Damage
COMPLETED · NA
-
Comparison of Pre-exercise Beta-hydroxy-beta-methylbutyrate Free Acid (HMB-FA) and Cold Water Therapy for the Attenuation of Muscle Damage and Soreness
COMPLETED · NA
-
The Long-term Effects of Oceanix™ on Resistance Training Adaptations
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI